Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors
- 26 September 2003
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 9 (5) , 578-583
- https://doi.org/10.1046/j.1365-2516.2003.00791.x
Abstract
Summary. We report the case of a 10.5‐year‐old boy with severe haemophilia A (SHA) and inhibitors who presented with superior vena cava (SVC) obstruction while on immune tolerance induction (ITI) with daily recombinant factor VIII (rFVIII) and factor eight bypassing activity (FEIBA) (75 U kg−1) twice a week. The boy had a right‐sided implanted central venous catheter. Imaging revealed a large occlusive thrombus in the SVC with all upper venous system drainage occurring through the azygos and collateral veins. Despite initial success with local thrombolytic therapy using recombinant tissue plasminogen activator, the thrombus persisted. Mechanical thrombolysis and angioplasty resulted in the successful removal of the thrombus and resolution of the SVC syndrome. Unfractionated heparin was used to prevent thrombus reformation/propagation. A work‐up did not reveal any underlying genetic prothrombotic risk factors. The occurrence of such a profoundly symptomatic thromboembolism (TE) in a boy with SHA with inhibitors is unusual. A combination of risk factors, including the ongoing infusion of high doses of FVIII in the context of a disappearance of inhibitors together with the infusion of clotting factors known to be potentially thrombogenic, may place haemophilic patients on ITI (immune tolerance induction) at risk for this rare, life‐threatening complication. The appropriate management of TEs in such a setting is unknown.Keywords
This publication has 25 references indexed in Scilit:
- Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse eventsHaemophilia, 2002
- Recombinant factor VIIa (Novoseven[reg ]) and the safety of treatmentSeminars in Hematology, 2001
- Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitorsBritish Journal of Haematology, 2000
- The use of central venous catheters (portacaths) in children with HaemophiliaHaemophilia, 2000
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia, 1999
- Port‐A‐Cath usage in children with haemophilia: experience of 53 casesActa Paediatrica, 1998
- Fatal Myocardial Necrosis Associated with Prothrombin-Complex–Concentrate Therapy in Hemophilia ANew England Journal of Medicine, 1983
- Acute myocardial infarction in a young hemophiliac patient during therapy with Factor IX concentrate and epsilon aminocaproic acidThe Journal of Pediatrics, 1981
- Antihemophilic factor inhibitors. Management with prothrombin complex concentratesJAMA, 1976
- Prothrombin concentrates in treatment of Christmas disease and allied disordersPublished by American Medical Association (AMA) ,1969